IL6 and Parkinson disease: Clinical studies support these immunomodulatory effects; for instance, a multi‐strain probiotic formulation significantly reduced circulating IL‐6 and TNF‐α levels in patients with Parkinson's disease [23], suggesting a decrease in neuroinflammation relevant to conditions such as depression, Alzheimer's disease, Parkinson's disease, MS, and ASD [24].